## Johnson & Johnson’s Tremfya Shows Promise in Crohn’s Disease: Phase 3 GRAVITI Study Results
Johnson & Johnson (JNJ) announced positive results from the Phase 3 GRAVITI study evaluating Tremfya (guselkumab) for the treatment of Crohn’s disease. The study demonstrated significant clinical remission and endoscopic response in adults with moderately to severely active Crohn’s disease, marking a potential breakthrough in managing this chronic inflammatory bowel disease.
The GRAVITI study, presented at the American College of Gastroenterology 2024, revealed compelling results across various time points. At week 12, over half of patients treated with Tremfya (400 mg administered subcutaneously) achieved clinical remission compared to only 21.4% in the placebo group. Similarly, endoscopic response was observed in 41.3% of the Tremfya-treated group versus 21.4% in the placebo group. These results highlight the rapid onset of action of Tremfya, with significant improvements in clinical remission evident as early as week 4.
Even more impressive results were observed at week 48. The rate of clinical remission was more than three times higher in patients receiving both maintenance doses of Tremfya (100 mg every eight weeks and 200 mg every four weeks) compared to the placebo group (60% and 66.1% versus 17.1%, respectively). The endoscopic response was also notably higher in both Tremfya maintenance groups (44.3% and 51.3%) compared to 6.8% in the placebo group.
These findings further strengthen the case for Tremfya as a potential treatment option for Crohn’s disease. The drug has already received FDA approval for moderately to severely active ulcerative colitis (UC), and an application for Crohn’s disease is currently under review. Regulatory applications have also been submitted in Europe seeking approval for both UC and Crohn’s disease.
The positive GRAVITI study results are expected to drive interest in Tremfya as a viable treatment option for Crohn’s disease. Investors seem to be optimistic, with JNJ stock up 0.29% at $161.34 at the time of writing.
